Loading
A phase 3 trial testing HB1801 in HER2-positive breast cancer, now recruiting.
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT07441460, led by Shanghai JMT-Bio, and recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of KN026 Combined With HB1801 and Chemotherapy Versus Trastuzumab Combined With Pertuzumab and Chemotherapy as Adjuvant Therapy in Resectable HER2-positive Breast Cancer. Planned enrolment is 1800 participants (estimated). The study started in 2026-03-06 and primary completion is expected in 2034-08-07. No results have been posted on ClinicalTrials.gov.
Shares HB1801, KN026, CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares HB1801, CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares KN026, CSPC Pharmaceutical Group.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer.